Otsuka Restructures Operations

Otsuka America Pharmaceutical, Inc. (OAPI) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) will restructure in an effort to grow the pharmaceutical business worldwide. As part of this initiative, Mark Altmeyer was appointed president and chief executive officer, OAPI, and Dean R. Haubrich, Ph.D., has been appointed chairman, OAPI board.

The restructuring includes establishing a Pharmaceutical Governance Committee and a Medical Device Governance Committee, responsible for regulatory compliance, cross-functional information sharing, reporting, CEO advisory, and the evaluation of new ideas and business proposals for OAPI.

OAPI and OPDC are also realigning shared services to increase efficiencies, including restructuring the human resources, risk management, business technology and brand strategy groups. In support of the company’s business technology and new IT operating model, OAPI has appointed Robert Mack as senior vice president, Business Technology. Mr. Mack will provide executive leadership for the vision, direction, execution and effectiveness of Otsuka’s Global IT functions, as well as its U.S. pharmaceutical affiliates.

“Otsuka’s restructuring will increase efficiencies across OAPI and OPDC, resulting in a stronger infrastructure that supports the growing needs of the organization,” said Mr. Altmeyer. “Energizing our North American operations will not only drive growth globally, but also increase our ability to attract top talent and establish strategic partnerships, both critical factors for our long-term success.”

OAPI plans to make additional investments in infrastructure, including the consolidation of sales groups into four business units: Oncology, Neuroscience, Hospital, and Medical Diagnostics and Devices.